MAPT and Alzheimer disease: In contrast, the pmEC seems to be largely spared from early tau pathology (Braak and Braak, 1985) and age- or preclinical AD-related vulnerability (Khan et al., 2014; Olsen et al., 2017; Reagh et al., 2018), and may not become affected until later in the disease process.